

ASX Announcement

USA Patent Granted for Recce's Antibiotics

SYDNEY, Australia, 14 March 2019: Recce Pharmaceuticals Ltd (ASX:RCE) (**Recce** or the **Company**), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, '*Copolymer and Method for Treatment of Bacterial Infection*'.

The USA represents close to half of the world's USD \$42.33 billion antibiotic market by value.^[1] This patent is Recce's second wholly owned patent to be Granted in USA and secures significant and additional monopolies for Recce to November 2035.

The Granted Patent contains a suite of 23 claims including its lead candidate RECCE® 327.

Recce's commercialisation strategy is focused on leveraging its expanding local and international intellectual property estate.

1- Allied Market Research (October 2018): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA